According to Yuyue Medical's announcement, the first half of 2026 achieved operating income of 4.569 billion yuan, a year-on-year decrease of 1.92%; net profit attributable to shareholders of listed companies was 843 million yuan, a year-on-year decrease of 29.92%; after deducting non-net profit of 761 million yuan, a year-on-year decrease of 16.69%. The company plans to pay a cash dividend of 4 yuan for every 10 shares, no bonus shares, and no capital increase from the Provident Fund. The company plans to repurchase shares for cancellation. The total repurchase capital is not less than 200 million yuan, no more than 400 million yuan, and the repurchase price is no more than 40 yuan/share. During the reporting period, the company's continuous glucose monitoring system was certified by the European Union MDR, and the semi-automatic external defibrillator obtained a medical device registration certificate; Mao Jianqiang, the deputy general manager, left office due to retirement.

According to Yuyue Medical's announcement, the first half of 2026 achieved operating income of 4.569 billion yuan, a year-on-year decrease of 1.92%; net profit attributable to shareholders of listed companies was 843 million yuan, a year-on-year decrease of 29.92%; after deducting non-net profit of 761 million yuan, a year-on-year decrease of 16.69%. The company plans to pay a cash dividend of 4 yuan for every 10 shares, no bonus shares, and no capital increase from the Provident Fund. The company plans to repurchase shares for cancellation. The total repurchase capital is not less than 200 million yuan, no more than 400 million yuan, and the repurchase price is no more than 40 yuan/share. During the reporting period, the company's continuous glucose monitoring system was certified by the European Union MDR, and the semi-automatic external defibrillator obtained a medical device registration certificate; Mao Jianqiang, the deputy general manager, left office due to retirement.